Product Datasheet

CD79A Antibody (IGA/1688R) [PerCP] NBP2-54469PCP

Unit Size: 100 ul

Store at 4C in the dark.

www.novusbio.com

technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-54469PCP

Updated 10/23/2024 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP2-54469PCP



NBP2-54469PCP

CD79A Antibody (IGA/1688R) [PerCP]

Product Information	
Unit Size	100 ul
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Monoclonal
Clone	IGA/1688R
Preservative	0.05% Sodium Azide
Isotype	IgG
Conjugate	PerCP
Purity	Protein A purified
Buffer	PBS
Product Description	
Description	This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Host	Rabbit
Gene ID	973
Gene Symbol	CD79A
Species	Human, Mouse, Rat
-	
Marker	B-Cell Marker
Marker Specificity/Sensitivity	B-Cell Marker A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
	A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of
Specificity/Sensitivity	A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Specificity/Sensitivity	A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Specificity/Sensitivity	A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of human CD79A protein (Uniprot: P11912)





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

Products Related to NBP2-54469PCP

NBP2-24891PCP	Rabbit IgG Isotype Control [PerCP]
NBP2-60209-50ug	Recombinant Human CD79A His Protein
7268-CT-100	CTLA-4 [Unconjugated]
9685-CD-050	CD79A [Unconjugated]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-54469PCP

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

www.novusbio.com

